{"database": "lobbying", "table": "lobbying_activities", "rows": [[3010107, "8c138b03-ef60-43bf-98ce-96b3c5932b22", "Q2", "BURRELL INTERNATIONAL GROUP LLC", 401103483, "ACER THERAPEUTICS", 2023, "second_quarter", "PHA", "COVID-19 therapeutics and Medical Countermeasures, Rare Disease, and Re-purposed drugs; Defense Appropriations for MCM Development", "HOUSE OF REPRESENTATIVES,SENATE", 20000, null, 0, 0, "2023-07-18T12:52:00-04:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["3010107"], "units": {}, "query_ms": 188.21702804416418, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}